Observational studyInternational journal of chronic obstructive pulmonary disease2016
A year in the life of German patients with COPD: the DACCORD observational study.
Observational study in International journal of chronic obstructive pulmonary disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.International journal of chronic obstructive pulmonary disease · 2018Trial
- Triple Therapy De-Escalation and Withdrawal of Inhaled Corticosteroids to Dual Bronchodilator Therapy in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Adjustments to maintenance therapy and the reasoning behind them among COPD outpatients in Austria: the STEP study.ERJ open research · 2024Article
- Rational use of inhaled corticosteroids for the treatment of COPD.NPJ primary care respiratory medicine · 2023Review
- In 'real world' patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations.Respiratory research · 2023Article
- LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations.Journal of clinical medicine · 2022Review
- Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world' study.Respiratory research · 2022Article
- Real-World Treatment of Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease: A Retrospective German Claims Data Analysis.International journal of chronic obstructive pulmonary disease · 2022Article
- COPD Exacerbation History and Impact on Future Exacerbations - 8-Year Retrospective Observational Database Cohort Study from Germany.International journal of chronic obstructive pulmonary disease · 2021Observational
- Observational
- The COPDnet integrated care model.International journal of chronic obstructive pulmonary disease · 2018Article
- Evaluation of the COPDnet integrated care model in patients with COPD: the study protocol.International journal of chronic obstructive pulmonary disease · 2018Article
- Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.International journal of chronic obstructive pulmonary disease · 2018Observational
- Longitudinal change of COPD assessment test (CAT) in a telehealthcare cohort is associated with exacerbation risk.International journal of chronic obstructive pulmonary disease · 2017Article
- "Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD.International journal of chronic obstructive pulmonary disease · 2017Article
- Stepwise management of COPD: What is next after bronchodilation?Therapeutic advances in respiratory diseaseReview
- COPD patients' characteristics, usual care, and adherence to guidelines: the Greek UNLOCK study.International journal of chronic obstructive pulmonary diseaseArticle
- Baseline patient demographics for TETRIS: a prospective, noninterventional study to characterize the use of triple therapy for COPD in Germany.Therapeutic advances in respiratory diseaseObservational
- Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries.International journal of chronic obstructive pulmonary diseaseReview
- COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.International journal of chronic obstructive pulmonary diseaseObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRandomized interventional trials generally recruit highly selected patients. In contrast, long-term, noninterventional studies can reflect standard of care of real-life populations. DACCORD (Die ambulante Versorgung mit langwirksamen Bronchodilatatoren: COPD-Register in Deutschland [Outpatient Care With Long-Acting Bronchodilators: COPD Registry in Germany]) is an ongoing observational study, conducted in primary and secondary care in Germany, aiming to describe the impact of disease and treatments on real-life patients with chronic obstructive pulmonary disease (COPD).
methodsPatients had a clinical and spirometry diagnosis of COPD, were aged ≥40 years, and were initiating or changing COPD maintenance medication. The only exclusion criteria were asthma and participation in a randomized clinical trial. Exacerbation data were collected every 3 months. COPD medication, COPD Assessment Test, and forced expiratory volume in 1 second (FEV1) were recorded at the end of the 1 year period.
resultsIn the 6 months prior to baseline, 26.5% of the 3,974 patients experienced ≥1 exacerbation, compared with 26.1% over the 1-year follow-up (annualized rate 0.384). Importantly, only previous exacerbations and not poor lung function alone predicted an increased exacerbation risk. There was a general shift to lower disease severity from baseline to 1 year, predominantly as a consequence of a lower proportion of patients considered at high risk due to exacerbations. COPD Assessment Test mean change from baseline was -1.9, with 48.9% of patients reporting a clinically relevant improvement. Overall persistence to medication was high, with 77.2% of patients still receiving the same class of medication at 1 year.
conclusionDACCORD suggests that in clinical practice, the large majority of COPD patients are symptomatic but seldom exacerbate and that widely used tools and treatment recommendations do not reflect this fully.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.